Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus Inc.

Evolus, Inc. ($EOLS) announced an update on their ongoing clinical study. The non-interventional post-authorisation safety study of NUCEIVA, also s...

Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CG Oncology, Inc. (CGON), Evolus (EOLS) and Nuvation...

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Evolus (EOLS) with...

Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Evolus (EOLS)

Evolus, Inc. (($EOLS)) has held its Q1 earnings call. Read on for the main highlights of the call. Evolus, Inc. struck an upbeat tone on its latest...

Evolus Earnings Call Highlights Profitable Growth Path

Evolus ( ($EOLS) ) has shared an update. Evolus terminated its unused at‑the‑market equity sales agreement with Leerink Partners LLC on May 1, 2026...

Evolus Ends ATM Facility After Strong Q1 Momentum

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Evolus (EOLS) and Bausch Health Companies (BHC). Evolus (EOLS) In...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EOLS	$6.57	+6.31%	976.69K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EOLS	$6.57	+6.3%	976.69K
3
4
5
6

EOLS

EOLS

No Data Available

Get Evolus Inc. Data in Excel

Get Evolus Inc. Data in Excel